| Original language | English |
|---|---|
| Pages (from-to) | 845-855 |
| Number of pages | 11 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2019 |
Cite this
EphA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer. / Martini, G.; Cardone, C.; Vitiello, P.P.; Belli, V.; Napolitano, S.; Troiani, T.; Ciardiello, D.; Della Corte, C.M.; Morgillo, F.; Matrone, N.; Sforza, V.; Papaccio, G.; Desiderio, V.; Paul, M.C.; Moreno-Viedma, V.; Normanno, N.; Rachiglio, A.M.; Tirino, V.; Maiello, E.; Latiano, T.P.; Rizzi, D.; Signoriello, G.; Sibilia, M.; Ciardiello, F.; Martinelli, E.
In: Molecular Cancer Therapeutics, Vol. 18, No. 4, 2019, p. 845-855.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - EphA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer
AU - Martini, G.
AU - Cardone, C.
AU - Vitiello, P.P.
AU - Belli, V.
AU - Napolitano, S.
AU - Troiani, T.
AU - Ciardiello, D.
AU - Della Corte, C.M.
AU - Morgillo, F.
AU - Matrone, N.
AU - Sforza, V.
AU - Papaccio, G.
AU - Desiderio, V.
AU - Paul, M.C.
AU - Moreno-Viedma, V.
AU - Normanno, N.
AU - Rachiglio, A.M.
AU - Tirino, V.
AU - Maiello, E.
AU - Latiano, T.P.
AU - Rizzi, D.
AU - Signoriello, G.
AU - Sibilia, M.
AU - Ciardiello, F.
AU - Martinelli, E.
N1 - Export Date: 26 June 2019
PY - 2019
Y1 - 2019
U2 - 10.1158/1535-7163.MCT-18-0539
DO - 10.1158/1535-7163.MCT-18-0539
M3 - Article
VL - 18
SP - 845
EP - 855
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 4
ER -